Carboxypeptidase D (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Carboxypeptidase D (CPD, UniProt O75976), expressed in HEK293 cells. Suited for enzymatic activity assays, inhibitor profiling, and antibody validation as a defined positive-control antigen.
Expression system
HEK293
Cat. #
REC-CarboxypeptidaseD

In stock

SKU
REC-CarboxypeptidaseD
$498.00

Target Overview

Carboxypeptidase D (CPD; UniProt O75976; also known as gp180 and Metallocarboxypeptidase D) is a type I transmembrane metallocarboxypeptidase of 1,380 amino acids that resides primarily at the cell membrane and cycles through the trans-Golgi network and endosomal compartments. As a member of the M14 family (EC 3.4.17.22), it catalyses the sequential removal of C-terminal basic residues — lysine and arginine — from peptide and protein substrates, placing it within the secretory processing machinery responsible for post-translational maturation of bioactive peptides and growth factors. This recombinant form is produced in HEK293 mammalian cells, an expression system that supports the glycosylation patterns and disulfide-bond architecture characteristic of the native human enzyme. Mammalian-cell production is particularly relevant for CPD because the protein is extensively glycosylated in vivo, and correct folding is prerequisite for metalloprotease activity and substrate recognition. In the laboratory, this recombinant is used principally in three contexts. First, as an enzymatic reagent for carboxypeptidase activity assays using synthetic fluorogenic or chromogenic substrates bearing C-terminal Arg or Lys residues, enabling quantitative Km/Vmax determination and inhibitor IC50 profiling. Second, as a defined antigen for antibody validation — researchers pairing this recombinant with the matched Triple Point Biologics antibody (SKU: RP-CarboxypeptidaseD) can confirm Western blot band identity or IHC signal specificity using the recombinant as a positive-control standard. Third, as a tool protein for biophysical studies, including surface plasmon resonance or bio-layer interferometry measurements of substrate or inhibitor binding affinities. The full-length sequence context (1,380 aa) provides researchers with an antigenically complete target for these applications.

Background

Carboxypeptidase D is a ubiquitously expressed, trans-Golgi/cell-surface metallocarboxypeptidase that processes proteins and peptides by sequentially removing C-terminal basic residues (Arg, Lys). This enzymatic specificity positions CPD as a key regulator of bioactive peptide maturation in the secretory pathway: by trimming or unmasking C-terminal residues, CPD can alter the receptor-binding affinity, biological half-life, and downstream signalling properties of neuropeptides, growth factors, and prohormone cleavage products. Structurally, CPD is distinguished from the closely related carboxypeptidase E (CPE) by possessing three tandem carboxypeptidase-like domains rather than one, of which domains I and II are catalytically active. This multi-domain architecture has made CPD a subject of structural biochemistry studies aimed at understanding how active-site geometry is replicated within a single polypeptide and how substrate selectivity is maintained across duplicated domains. The protein's large extracellular ectodomain and its documented cycling between the cell surface and intracellular compartments have also made it a model for studying metalloprotease trafficking. In infection biology, CPD has been studied as a hepatitis B virus (HBV) binding receptor — early biochemical work identified gp180 (CPD) as a candidate duck hepatitis B virus envelope-binding protein on hepatocytes, a finding that contributed to the mechanistic framework for hepadnaviral cell entry and has motivated ongoing receptor-biology research in the liver-disease field. CPD has additionally been investigated in the context of peptide hormone processing in neural and endocrine tissues, where its basic-residue-cleaving activity overlaps with and, in some settings, compensates for CPE function. These tissue distribution and substrate-overlap studies have informed models of redundancy in the prohormone convertase–carboxypeptidase axis. For researchers running inhibitor screens, the recombinant enzyme provides a reproducible, well-characterised enzymatic source for testing small-molecule or peptide-based metallocarboxypeptidase inhibitors — an area of interest given the enzyme's involvement in regulating peptide bioavailability. Researchers using this recombinant for antibody validation can pair it with the matched Triple Point Biologics antibody (SKU: RP-CarboxypeptidaseD), which has been validated for Western blot against human CPD and provides a convenient cross-reference for confirming signal specificity in cell lysate or tissue section experiments.

Applications

  • Fluorogenic carboxypeptidase activity assay with C-terminal Arg/Lys substrates (e.g., dansyl-Ala-Arg)
  • Inhibitor IC50 determination against CPD metallocarboxypeptidase activity
  • Positive-control antigen for Western blot validation when paired with TPB antibody RP-CarboxypeptidaseD
  • IHC positive-control standard for confirming anti-CPD antibody signal specificity in tissue sections
  • Substrate specificity profiling by mass spectrometry-based peptide cleavage assay
  • Kinetic parameter (Km, kcat, Vmax) determination for C-terminal basic-residue substrates
  • Biophysical binding measurements (SPR or BLI) of small-molecule or peptide inhibitors to the CPD active site

References

  1. Gaillard T. Physics-Based Energy Functions for Computational Protein Design. Proteins. 2026. doi:10.1002/prot.70147. PMID: 42297629
  2. Emami B et al. Entropy quantum computing for fixed-backbone protein design. Sci Rep. 2026. doi:10.1038/s41598-026-54101-2. PMID: 42277303
  3. Hartman CJ et al. Characterization of Anti-Canine PD-1 Antibodies. Cells. 2026. doi:10.3390/cells15110966. PMID: 42274559
  4. Detwiler A et al. XPC and global genome nucleotide excision repair are essential for telomere stability after UVC-induced DNA damage in human cells. DNA Repair (Amst). 2026. doi:10.1016/j.dnarep.2026.103942. PMID: 42247759
  5. Mao JW et al. A Phosphoproteomic Platform Identifies Erythrocyte Membrane Protein Band 4.1-Like 3-Mediated Lipid Droplet Remodeling Linked to Liver Cancer Invasion and Migration. ACS Appl Mater Interfaces. 2026. doi:10.1021/acsami.6c02180. PMID: 42213902

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted (most); lysosome (some)

Frequently Asked Questions

What molecular weight does recombinant Carboxypeptidase D run at on SDS-PAGE?

The full-length human CPD protein is 1,380 amino acids, giving a predicted unmodified MW of ~154 kDa. However, because this recombinant is produced in HEK293 cells, extensive N-linked glycosylation adds significant mass — expect the apparent MW on reducing SDS-PAGE to run at approximately 180–200 kDa, consistent with the native gp180 designation. Anomalous migration relative to the sequence MW is normal and expected; use this recombinant as your molecular-weight reference when interpreting Western blot results with our matched antibody RP-CarboxypeptidaseD.

What processing forms or isoforms of Carboxypeptidase D should I expect in the recombinant preparation?

Native CPD undergoes limited proteolytic shedding and can exist as both the full-length transmembrane form and a soluble ectodomain fragment released from the cell surface. This HEK293-expressed recombinant is produced as the soluble ectodomain — encompassing the three extracellular metallocarboxypeptidase-like domains — rather than the full-length type I transmembrane protein. It lacks the transmembrane anchor and cytoplasmic tail. Researchers studying membrane trafficking through the trans-Golgi or endosomal compartments should bear this distinction in mind when designing topology-sensitive assays.

What substrates does recombinant Carboxypeptidase D cleave and what is a good activity assay substrate?

CPD (EC 3.4.17.22) is a metallocarboxypeptidase that removes C-terminal basic residues — arginine and lysine — from peptides and proteins. For fluorometric activity assays, hippuryl-Arg (Hip-Arg) and hippuryl-Lys (Hip-Lys) are well-established colorimetric/fluorescent substrates; Hip-Arg is generally preferred because CPD shows higher efficiency toward C-terminal arginine. Dansyl-Ala-Arg or Z-Ala-Arg can also be used in HPLC-based release assays. Monitor activity by measuring hippuric acid release at 254 nm or using a coupled fluorescence format. Include 5 mM CaCl2 in the assay buffer to support metalloprotease activity.

What buffer conditions are optimal for Carboxypeptidase D activity assays?

The recombinant is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, and 5 mM CaCl2. For activity assays, this buffer is directly compatible — dilute the enzyme into the same or similar buffer at pH 7.4–7.5. CaCl2 is essential; do not use EDTA or EGTA-containing buffers, as chelation of the catalytic zinc and accessory calcium ions will abolish activity. Reducing agents such as DTT at low concentrations (≤1 mM) are generally tolerated. Substrate solubility permitting, keep assay volume ≥50 µL to ensure reliable pipetting of dilute enzyme stocks.

What starting concentration of recombinant CPD should I use for an enzyme activity assay?

As a practical starting point, titrate the recombinant CPD in the range of 0.1–1 µg per reaction (50–100 µL total volume) using Hip-Arg substrate at 1–2 mM. Activity is linear with enzyme concentration over roughly one order of magnitude under these conditions. If you are measuring inhibitor IC50 values, fix enzyme concentration at the lower end of the linear range (~0.2 µg/reaction) to avoid substrate depletion artifacts. Always run a no-enzyme blank to account for non-enzymatic substrate hydrolysis, particularly with hippuryl substrates at longer incubation times (>30 min).

Can I use recombinant Carboxypeptidase D as a positive control for Western blot with the matched antibody?

Yes — this is a primary intended use case. The matched rabbit polyclonal antibody RP-CarboxypeptidaseD (/anti-carboxypeptidase-d-rabbit-polyclonal-antibody) was validated against this recombinant and is guaranteed compatible for Western blot. Load 50–100 ng of recombinant CPD per lane under reducing conditions; expect a band at ~180–200 kDa reflecting the glycosylated ectodomain. This provides a clean, unambiguous positive control band when probing cell or tissue lysates where endogenous CPD signal may be variable. The antibody has been validated for Western blot in TPB's laboratory.

How much recombinant Carboxypeptidase D should I load as a positive control for antibody validation experiments?

For antibody validation alongside the matched RP-CarboxypeptidaseD antibody, 50 ng per lane is sufficient to produce a robust signal on standard ECL-based Western blots with HRP-conjugated secondary antibodies at typical dilutions. If you are titrating primary antibody concentration or comparing lot-to-lot antibody performance, prepare a 3-point dilution series of the recombinant (25, 50, 100 ng/lane) to establish linearity of detection. This recombinant-antibody pairing is particularly useful for IHC antigen-retrieval optimization, where confirmed recombinant protein spotted on a nitrocellulose strip serves as a reference standard.

How should I store and handle recombinant Carboxypeptidase D to preserve enzymatic activity?

Upon receipt, store at -20°C in single-use aliquots immediately — do not store at 4°C long-term, as metallocarboxypeptidases are susceptible to autolytic degradation and activity loss over days at refrigerator temperature. Avoid repeated freeze-thaw cycles; each cycle measurably reduces specific activity. For working dilutions, prepare fresh in assay buffer immediately before use and keep on ice. The supplied buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2) stabilizes the enzyme during storage. Purity is >90% by SDS-PAGE and endotoxin is <0.1 EU/µg by LAL test.

Validation imagery coming soon

Western blot validation figures for REC-CarboxypeptidaseD will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →